ket No.: 15966-581 CIP

Express Mail Label: EV074978553US Date of Deposit: May 22, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

13.11.62

APPLICANTS:

FILING DATE:

Quinn, et al.

SERIAL NUMBER:

09/996,015

November 28, 2001

EXAMINER:

Not Yet Assigned

1652 ART UNIT: Aortic Carboxypeptidase-Like Proteins and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents Washington, D.C. 20231

FOR:

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents: RECEIVED

1. Information Disclosure Statement (2 pages), in duplicate;

2. Modified Form 1449/PTO (2 pages), in duplicate;

3. Copies of Cited References B1-B4 and C29-C30; and

4. Return Postcard

TECH CENTER 1600/2900

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 15966-581 CIP. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: May 22, 2002

TRA 1670990v1

OIDELICMS 7002 E-NOC **BECEINED** 6

Express Mail Label No.: EV074978553US

MAY 2 2 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PADE PPLICANTS:

Quinn, et al.

SERIAL NUMBER:

09/996,015

EXAMINER: Not Yet Assigned

FILING DATE:

November 28, 2001

ART UNIT:

1652

For:

Aortic Carboxypeptidase-Like Proteins and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents Washington, D.C. 20231

RECEIVED

INFORMATION DISCLOSURE STATEMENT

JUN 1 8 0002

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, TECH CENTER 1600/2900 hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

A copy of each of the references in the above-identified application is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS:

Quinn, et al.

U.S.S.N.:

09/996,015

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-581 CIP.

Respectfully submitted,

Ivor R. Ekrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: May 22, 2002

TRA 1670983v1

RECEIVED

Page 1 of 2

JUN 2 8 3002

OIP Eplocatype a plus sign (+) in this box

TECH CENTER 1600/2900 PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Middified Form 1449/PTO

MAY 2 2 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

09/996,015 **Application Number** 11/28/2001 Filing Date First Named inventor Quinn Group Art Unit 1652 **Examiner Name** Not Yet Assigned **Attorney Docket Number** 15966-581 CIP

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.			Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	wo	98/39446	Human Genome Sciences, Inc.	09/11/1998		
	B2	wo	00/58473	CuraGen, Corp.	10/05/2000		
	В3	wo	01/10903	Incyte Genomics, Inc.	02/15/2001		
	B4	EP	1 067 182	Helix Res. Inst.	01/10/2001		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1*	Brownstein, , et al. (1980). "Synthesis, transport, and release of posterior pituitary hormones." <i>Science</i> 207(4429): 373-8.					
	C2*	DeCruz, et al. (1996). "The basis for somatic gene therapy of cancer." <i>J Exp Ther Oncol</i> 1(2): 73-83. ABSTRACT ONLY					
	C3*	Fricker and Leiter (1999). "Peptides, enzymes and obesity: new insights from a 'dead' enzyme." Trends Biochem Sci 24(10): 390-3.					
	C4*	EMBL Database Accession Number: Q61281 (11/01/96).					
	C5*	EMBL Database Accession Number: Q14113 (11/01/96).					
	C6*	EMBL Database Accession Number: O88442 (11/01/98).					
	C7*	Layne, et al. (1998). "Aortic carboxypeptidase-like protein, a novel protein with discoidin and carboxypeptidase-like domains, is up-regulated during vascular smooth muscle cell differentiation." <i>J Biol Chem</i> 273(25): 15654-60.					
	C8*	EMBL Database Accession Number: AF077738 (03/11/99).					
	C9*	GenBank Accession Number: Q9Z100 (05/01/99).					
	C10*	Lei, et al. (1999). "Identification of mouse CPX-1, a novel member of the metallocarboxypeptidase gene family with highest similarity to CPX-2." DNA Cell Biol 18(2): 175-85.					
	C11*	SWISS-PROT Database Accession Number: ALO35460 (10/01/00).					
	C12*	McGwire, et al. (1997). "Identification of a membrane-bound carboxypeptidase as the mammalian homolog of duck gp180, a hepatitis B virus-binding protein." <i>Life Sci</i> 60(10): 715-24.					
	C13*	Muise and Ro (1999). "Enzymic characterization of a novel member of the regulatory B-like carboxypeptidase with transcriptional repression function: stimulation of enzymic activity by its target DNA." Biochem J 343 Pt 2: 341-5.					
	C14*	Nagg rt, t al. (1995). "Hyperproinsulinaemia in obese fat/fat mice assoclated with a					

Expr ss Mail N .: EV074978553US Dat of D posit: May 22, 2002

TRADEN

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Exam	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.						
25		carboxypeptidase E mutation which reduces enzyme activity." Nat Genet 10(2): 135-42. ABSTRACT ONLY						
040	C15*	Ohno, et al. (1996). "A cDNA cloning of human AEBP1 from primary cultured osteoblasts and its expression in a differentiating osteoblastic cell line." Biochem Biophys Res Commun 228(2): 411-4.						
	C16*	Ollas, et al. (1996). "Heterologous expression of human vasopressin-neurophysin precursors in a pituitary cell line: defective transport of a mutant protein from patients with familial diabetes insipidus." DNA Cell Biol 15(11): 929-35.						
	C17*	Rehli, et al. (1995). "Carboxypeptidase M is identical to the MAX.1 antigen and its expression is associated with monocyte to macrophage differentiation." J Biol Chem 270(26): 15644-9.						
	C18*	Repaske and Browning (1994). "A de novo mutation in the coding sequence for neurophysin-II (Pro24->Leu) is associated with onset and transmission of autosomal dominant neurohypophyseal diabetes insipidus." J Clin Endocrinol Metab 79(2): 421-7.						
	C19*	Sachs, et al. (1969). "Biosynthesis and release of vasopressin and neurophysin." Recent Prog Horm Res 25: 447-91.						
	C20*	Saez, et al. (1997). "Inducible gene expression in mammalian cells and transgenic mice." Curr Opin Biotechnol 8(5): 608-16.						
	C21*	Sawada and Kamataki (1998). "Genetically engineered cells stably expressing cytochrome P450 and their application to mutagen assays." <i>Mutat Res</i> 411(1): 19-43.						
	C22*	Schmale, et al. (1984). "The mutant vasopressin gene from diabetes insipidus (Brattleboro) rats is transcribed but the message is not efficiently translated." <i>Embo J</i> 3(13): 3289-93.						
	C23*	Seed (1987). "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2." Nature 329(6142): 840-2. ABSTRACT ONLY						
	C24*	Song and Fricker (1997). "Cloning and expression of human carboxypeptidase Z, a novel metallocarboxypeptidase." <i>J Biol Chem</i> 272(16): 10543-50.						
	C25*	Tan, et al. (1989). "Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins." <i>Anesthesiology</i> 70(2): 267-75.						
	C26*	Vogel (1999). "Discoidin domain receptors: structural relations and functional implications." Faseb J 13(Suppl): S77-82.						
	C27*	EMBL Database Accession Number: O54860 (06/01/98).						
	C28*	Xin, et al. (1998). "Identification of mouse CPX-2, a novel member of the metallocarboxypeptidase gene family: cDNA cloning, mRNA distribution, and protein expression and characterization." DNA Cell Biol 17(10): 897-909.						
	C29	EMBL Database Accession Number: Q9NUB5 (10/01/00).						
	C30	International Search Report for PCT/US00/28364. Mailed on 7/26/2001.						

^{*} a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/641,741, filed August 18, 2000, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

RECEIVED

JUN 2 R 2002

TECH CENTER 1600/2900